Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY

CASTLE BIOSCIENCES INC

2025-FY EPS reported -$0.83 revenue$344,229,000

2025 total revenue >$340M, above guided range of $327-335M.
Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.
DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.
Year-end cash + marketable securities ~$300M.
AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.